EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Mass cytometric single cell immune profiles of peripheral blood from acute myeloid leukemia patients in complete remission with measurable residual disease

Øystein Sefland, Stein-Erik Gullaksen, Maria Omsland, Håkon Reikvam, Eivind Galteland, Hoa Thi Tuyet Tran, Signe Spetalen, Satwinder Kaur Singh, Hester J T Van Zeeburg, Arjan A Van De Loosdrecht, Bjørn Tore Gjertsen

Cytometry Part B: Clinical Cytometry · 2024

DOI: 10.1002/cyto.b.22197 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, 2024. Verfasst von Øystein Sefland und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Neoplasm, Residual, Flow Cytometry, Remission Induction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Helse Vest Health Trust projects, Helse Vest.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Measurable residual disease (MRD) is detected in approximately a quarter of AML chemotherapy responders, serving as a predictor for relapse and shorter survival. Immunological control of residual disease is suggested to prevent relapse, but the mechanisms involved are not fully understood. We present a peripheral blood single cell immune profiling by mass cytometry using a 42‐antibody panel with particular emphasis on markers of cellular immune response. Six healthy donors were compared with four AML patients with MRD (MRD + ) in first complete remission (CR1 MRD+ ). Three of four patients demonstrated a favorable genetic risk profile, while the fourth patient had an unfavorable risk profile (complex karyotype, TP53‐mutation) and a high level of MRD. Unsupervised clustering using self‐organizing maps and dimensional reduction analysis was performed for visualization and analysis of immune cell subsets. CD57 + natural killer (NK)‐cell subsets were found to be less abundant in patients than in healthy donors. Both T and NK cells demonstrated elevated expression of activity and maturation markers (CD44, granzyme B, and phosho‐STAT5 Y694) in patients. Although mass cytometry remains an expensive method with limited scalability, our data suggest the utility for employing a 42‐plex profiling for cellular immune surveillance in whole blood, and possibly as a biomarker platform in future clinical trials. The findings encourage further investigations of single cell immune profiling in CR1 MRD+ AML‐patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteNeoplasm, ResidualFlow CytometryRemission InductionSingle-Cell AnalysisHumansMaleMiddle AgedFemaleImmunophenotypingAdultKiller Cells, NaturalAgedPathologic Complete Response

Stichwörter der Autor:innen

acute myeloid leukemiadendritic cell therapyimmune profilingmass cytometrysingle cell analysis

Autor:innen und Institutionen

  • Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Department of Medicine, Section of Hematology, Haukeland University Hospital, Bergen, Norway.
  • K.G. Jebsen Centre for Myeloid Blood Cancer, Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Department of Safety, Chemistry, and Biomedical Laboratory Sciences, Western Norway University of Applied Sciences, Bergen, Norway.
  • Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Department of Haematology, Oslo University Hospital, Oslo, Norway.

Förderung

  • Helse Vest Health Trust projects
  • Helse Vest

Zitieren

APA

Sefland, Ø., Gullaksen, S. E., Omsland, M., Reikvam, H., Galteland, E., Tran, H. T. T., Spetalen, S., Singh, S. K., Van Zeeburg, H. J. T., Van De Loosdrecht, A. A., & Gjertsen, B. T. (2024). Mass cytometric single cell immune profiles of peripheral blood from acute myeloid leukemia patients in complete remission with measurable residual disease. Cytometry Part B: Clinical Cytometry. https://doi.org/10.1002/cyto.b.22197

Vancouver

Sefland Ø, Gullaksen SE, Omsland M, Reikvam H, Galteland E, Tran HTT, et al. Mass cytometric single cell immune profiles of peripheral blood from acute myeloid leukemia patients in complete remission with measurable residual disease. Cytometry Part B: Clinical Cytometry. 2024. doi:10.1002/cyto.b.22197

BibTeX
@article{Sefland2024,
  author = {Sefland, Øystein and Gullaksen, Stein-Erik and Omsland, Maria and Reikvam, Håkon and Galteland, Eivind and Tran, Hoa Thi Tuyet and Spetalen, Signe and Singh, Satwinder Kaur and Van Zeeburg, Hester J T and Van De Loosdrecht, Arjan A and Gjertsen, Bjørn Tore},
  title = {Mass cytometric single cell immune profiles of peripheral blood from acute myeloid leukemia patients in complete remission with measurable residual disease},
  journal = {Cytometry Part B: Clinical Cytometry},
  year = {2024},
  doi = {10.1002/cyto.b.22197}
}
Kostenlos starten →